Logo image of CYTK

CYTOKINETICS INC (CYTK) Stock Fundamental Analysis

NASDAQ:CYTK - Nasdaq - US23282W6057 - Common Stock - Currency: USD

50.35  +1.15 (+2.34%)

Fundamental Rating

2

Overall CYTK gets a fundamental rating of 2 out of 10. We evaluated CYTK against 572 industry peers in the Biotechnology industry. CYTK has a bad profitability rating. Also its financial health evaluation is rather negative. CYTK is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CYTK had negative earnings in the past year.
CYTK had a negative operating cash flow in the past year.
CYTK had negative earnings in each of the past 5 years.
CYTK had negative operating cash flow in 4 of the past 5 years.
CYTK Yearly Net Income VS EBIT VS OCF VS FCFCYTK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100M -200M -300M -400M -500M

1.2 Ratios

CYTK's Return On Assets of -40.14% is in line compared to the rest of the industry. CYTK outperforms 56.46% of its industry peers.
Industry RankSector Rank
ROA -40.14%
ROE N/A
ROIC N/A
ROA(3y)-42.59%
ROA(5y)-38.72%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CYTK Yearly ROA, ROE, ROICCYTK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500 1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CYTK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CYTK Yearly Profit, Operating, Gross MarginsCYTK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K

More info and screens

3

2. Health

2.1 Basic Checks

CYTK does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CYTK has been increased compared to 1 year ago.
CYTK has more shares outstanding than it did 5 years ago.
CYTK has a worse debt/assets ratio than last year.
CYTK Yearly Shares OutstandingCYTK Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
CYTK Yearly Total Debt VS Total AssetsCYTK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

2.2 Solvency

CYTK has an Altman-Z score of -0.53. This is a bad value and indicates that CYTK is not financially healthy and even has some risk of bankruptcy.
CYTK has a better Altman-Z score (-0.53) than 62.12% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -0.53
ROIC/WACCN/A
WACC10.28%
CYTK Yearly LT Debt VS Equity VS FCFCYTK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M -400M 600M

2.3 Liquidity

A Current Ratio of 9.28 indicates that CYTK has no problem at all paying its short term obligations.
CYTK has a better Current ratio (9.28) than 77.70% of its industry peers.
CYTK has a Quick Ratio of 9.28. This indicates that CYTK is financially healthy and has no problem in meeting its short term obligations.
CYTK has a better Quick ratio (9.28) than 77.88% of its industry peers.
Industry RankSector Rank
Current Ratio 9.28
Quick Ratio 9.28
CYTK Yearly Current Assets VS Current LiabilitesCYTK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 2.54% over the past year.
The Revenue for CYTK has decreased by -58.84% in the past year. This is quite bad
CYTK shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -24.89% yearly.
EPS 1Y (TTM)2.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-0.74%
Revenue 1Y (TTM)-58.84%
Revenue growth 3Y-48.71%
Revenue growth 5Y-24.89%
Sales Q2Q%22.49%

3.2 Future

Based on estimates for the next years, CYTK will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.25% on average per year.
The Revenue is expected to grow by 135.92% on average over the next years. This is a very strong growth
EPS Next Y1.94%
EPS Next 2Y-0.49%
EPS Next 3Y7.5%
EPS Next 5Y18.25%
Revenue Next Year-66.75%
Revenue Next 2Y64.2%
Revenue Next 3Y151.77%
Revenue Next 5Y135.92%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CYTK Yearly Revenue VS EstimatesCYTK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B
CYTK Yearly EPS VS EstimatesCYTK Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CYTK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CYTK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CYTK Price Earnings VS Forward Price EarningsCYTK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYTK Per share dataCYTK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4 -5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.49%
EPS Next 3Y7.5%

More info and screens

0

5. Dividend

5.1 Amount

CYTK does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CYTOKINETICS INC

NASDAQ:CYTK (2/5/2025, 10:44:57 AM)

50.35

+1.15 (+2.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)02-20 2025-02-20/amc
Inst Owners116.46%
Inst Owner Change-0.27%
Ins Owners0.43%
Ins Owner Change1.24%
Market Cap5.94B
Analysts80
Price Target84.12 (67.07%)
Short Float %12.13%
Short Ratio11.78
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-14.2%
Min EPS beat(2)-21.59%
Max EPS beat(2)-6.82%
EPS beat(4)0
Avg EPS beat(4)-20.5%
Min EPS beat(4)-39.39%
Max EPS beat(4)-6.82%
EPS beat(8)0
Avg EPS beat(8)-25.7%
EPS beat(12)2
Avg EPS beat(12)-8.59%
EPS beat(16)2
Avg EPS beat(16)-16.5%
Revenue beat(2)0
Avg Revenue beat(2)-67.76%
Min Revenue beat(2)-73.51%
Max Revenue beat(2)-62.02%
Revenue beat(4)0
Avg Revenue beat(4)-57.33%
Min Revenue beat(4)-84.78%
Max Revenue beat(4)-9%
Revenue beat(8)1
Avg Revenue beat(8)-46.16%
Revenue beat(12)3
Avg Revenue beat(12)218.27%
Revenue beat(16)3
Avg Revenue beat(16)158.06%
PT rev (1m)-0.79%
PT rev (3m)0.07%
EPS NQ rev (1m)5.34%
EPS NQ rev (3m)-10.72%
EPS NY rev (1m)0.51%
EPS NY rev (3m)-1.06%
Revenue NQ rev (1m)-13.83%
Revenue NQ rev (3m)85.52%
Revenue NY rev (1m)-0.69%
Revenue NY rev (3m)-13.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1845.85
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.38
EYN/A
EPS(NY)-5.5
Fwd EYN/A
FCF(TTM)-3.45
FCFYN/A
OCF(TTM)-3.43
OCFYN/A
SpS0.03
BVpS-0.12
TBVpS-0.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -40.14%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.59%
ROA(5y)-38.72%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.97%
Cap/Sales 83.63%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.28
Quick Ratio 9.28
Altman-Z -0.53
F-Score4
WACC10.28%
ROIC/WACCN/A
Cap/Depr(3y)783.5%
Cap/Depr(5y)631.49%
Cap/Sales(3y)33.4%
Cap/Sales(5y)25.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-0.74%
EPS Next Y1.94%
EPS Next 2Y-0.49%
EPS Next 3Y7.5%
EPS Next 5Y18.25%
Revenue 1Y (TTM)-58.84%
Revenue growth 3Y-48.71%
Revenue growth 5Y-24.89%
Sales Q2Q%22.49%
Revenue Next Year-66.75%
Revenue Next 2Y64.2%
Revenue Next 3Y151.77%
Revenue Next 5Y135.92%
EBIT growth 1Y-5.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-17.79%
EBIT Next 3Y1.5%
EBIT Next 5Y23.91%
FCF growth 1Y-49.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-64.33%
OCF growth 3YN/A
OCF growth 5YN/A